id	sid	tid	token	lemma	pos
g158bg28j3g	1	1	leishmaniasis	leishmaniasis	NOUN
g158bg28j3g	1	2	is	be	AUX
g158bg28j3g	1	3	a	a	DET
g158bg28j3g	1	4	group	group	NOUN
g158bg28j3g	1	5	of	of	ADP
g158bg28j3g	1	6	vector	vector	NOUN
g158bg28j3g	1	7	-	-	PUNCT
g158bg28j3g	1	8	borne	bear	VERB
g158bg28j3g	1	9	,	,	PUNCT
g158bg28j3g	1	10	parasitic	parasitic	ADJ
g158bg28j3g	1	11	diseases	disease	NOUN
g158bg28j3g	1	12	caused	cause	VERB
g158bg28j3g	1	13	by	by	ADP
g158bg28j3g	1	14	over	over	ADP
g158bg28j3g	1	15	20	20	NUM
g158bg28j3g	1	16	species	specie	NOUN
g158bg28j3g	1	17	of	of	ADP
g158bg28j3g	1	18	the	the	DET
g158bg28j3g	1	19	protozoan	protozoan	NOUN
g158bg28j3g	1	20	,	,	PUNCT
g158bg28j3g	1	21	leishmania	leishmania	PROPN
g158bg28j3g	1	22	spp	spp	PROPN
g158bg28j3g	1	23	.	.	PUNCT
g158bg28j3g	2	1	the	the	DET
g158bg28j3g	2	2	three	three	NUM
g158bg28j3g	2	3	major	major	ADJ
g158bg28j3g	2	4	disease	disease	NOUN
g158bg28j3g	2	5	classifications	classification	NOUN
g158bg28j3g	2	6	,	,	PUNCT
g158bg28j3g	2	7	cutaneous	cutaneous	ADJ
g158bg28j3g	2	8	,	,	PUNCT
g158bg28j3g	2	9	visceral	visceral	NOUN
g158bg28j3g	2	10	,	,	PUNCT
g158bg28j3g	2	11	and	and	CCONJ
g158bg28j3g	2	12	mucocutaneous	mucocutaneous	ADJ
g158bg28j3g	2	13	,	,	PUNCT
g158bg28j3g	2	14	have	have	VERB
g158bg28j3g	2	15	a	a	DET
g158bg28j3g	2	16	range	range	NOUN
g158bg28j3g	2	17	of	of	ADP
g158bg28j3g	2	18	clinical	clinical	ADJ
g158bg28j3g	2	19	manifestations	manifestation	NOUN
g158bg28j3g	2	20	,	,	PUNCT
g158bg28j3g	2	21	ranging	range	VERB
g158bg28j3g	2	22	from	from	ADP
g158bg28j3g	2	23	self	self	NOUN
g158bg28j3g	2	24	-	-	PUNCT
g158bg28j3g	2	25	healing	heal	VERB
g158bg28j3g	2	26	skin	skin	NOUN
g158bg28j3g	2	27	lesions	lesion	NOUN
g158bg28j3g	2	28	to	to	ADP
g158bg28j3g	2	29	hepatosplenomegaly	hepatosplenomegaly	PROPN
g158bg28j3g	2	30	and	and	CCONJ
g158bg28j3g	2	31	mucosal	mucosal	NOUN
g158bg28j3g	2	32	membrane	membrane	NOUN
g158bg28j3g	2	33	damage	damage	NOUN
g158bg28j3g	2	34	to	to	ADP
g158bg28j3g	2	35	fatality	fatality	NOUN
g158bg28j3g	2	36	.	.	PUNCT
g158bg28j3g	3	1	as	as	ADP
g158bg28j3g	3	2	a	a	DET
g158bg28j3g	3	3	category	category	NOUN
g158bg28j3g	3	4	i	i	PRON
g158bg28j3g	3	5	neglected	neglect	VERB
g158bg28j3g	3	6	tropical	tropical	ADJ
g158bg28j3g	3	7	disease	disease	NOUN
g158bg28j3g	3	8	,	,	PUNCT
g158bg28j3g	3	9	leishmaniasis	leishmaniasis	NOUN
g158bg28j3g	3	10	represents	represent	VERB
g158bg28j3g	3	11	a	a	DET
g158bg28j3g	3	12	major	major	ADJ
g158bg28j3g	3	13	international	international	ADJ
g158bg28j3g	3	14	health	health	NOUN
g158bg28j3g	3	15	challenge	challenge	NOUN
g158bg28j3g	3	16	with	with	ADP
g158bg28j3g	3	17	over	over	ADP
g158bg28j3g	3	18	1	1	NUM
g158bg28j3g	3	19	billion	billion	NUM
g158bg28j3g	3	20	people	people	NOUN
g158bg28j3g	3	21	living	live	VERB
g158bg28j3g	3	22	in	in	ADP
g158bg28j3g	3	23	disease	disease	NOUN
g158bg28j3g	3	24	-	-	PUNCT
g158bg28j3g	3	25	endemic	endemic	ADJ
g158bg28j3g	3	26	areas	area	NOUN
g158bg28j3g	3	27	.	.	PUNCT
g158bg28j3g	4	1	as	as	ADP
g158bg28j3g	4	2	of	of	ADP
g158bg28j3g	4	3	2018	2018	NUM
g158bg28j3g	4	4	,	,	PUNCT
g158bg28j3g	4	5	cutaneous	cutaneous	ADJ
g158bg28j3g	4	6	leishmaniasis	leishmaniasis	NOUN
g158bg28j3g	4	7	is	be	AUX
g158bg28j3g	4	8	endemic	endemic	ADJ
g158bg28j3g	4	9	in	in	ADP
g158bg28j3g	4	10	92	92	NUM
g158bg28j3g	4	11	countries	country	NOUN
g158bg28j3g	4	12	and	and	CCONJ
g158bg28j3g	4	13	territories	territory	NOUN
g158bg28j3g	4	14	while	while	SCONJ
g158bg28j3g	4	15	visceral	visceral	ADJ
g158bg28j3g	4	16	leishmaniasis	leishmaniasis	NOUN
g158bg28j3g	4	17	is	be	AUX
g158bg28j3g	4	18	endemic	endemic	ADJ
g158bg28j3g	4	19	in	in	ADP
g158bg28j3g	4	20	83	83	NUM
g158bg28j3g	4	21	countries	country	NOUN
g158bg28j3g	4	22	and	and	CCONJ
g158bg28j3g	4	23	territories	territory	NOUN
g158bg28j3g	4	24	.	.	PUNCT
g158bg28j3g	5	1	the	the	DET
g158bg28j3g	5	2	first	first	ADJ
g158bg28j3g	5	3	line	line	NOUN
g158bg28j3g	5	4	chemotherapeutics	chemotherapeutic	NOUN
g158bg28j3g	5	5	used	use	VERB
g158bg28j3g	5	6	to	to	PART
g158bg28j3g	5	7	treat	treat	VERB
g158bg28j3g	5	8	leishmaniasis	leishmaniasis	NOUN
g158bg28j3g	5	9	are	be	AUX
g158bg28j3g	5	10	intravenous	intravenous	ADJ
g158bg28j3g	5	11	pentavalent	pentavalent	ADJ
g158bg28j3g	5	12	antimonials	antimonial	NOUN
g158bg28j3g	5	13	;	;	PUNCT
g158bg28j3g	5	14	however	however	ADV
g158bg28j3g	5	15	,	,	PUNCT
g158bg28j3g	5	16	these	these	DET
g158bg28j3g	5	17	drugs	drug	NOUN
g158bg28j3g	5	18	have	have	VERB
g158bg28j3g	5	19	harsh	harsh	ADJ
g158bg28j3g	5	20	side	side	NOUN
g158bg28j3g	5	21	effects	effect	NOUN
g158bg28j3g	5	22	and	and	CCONJ
g158bg28j3g	5	23	prolonged	prolong	VERB
g158bg28j3g	5	24	,	,	PUNCT
g158bg28j3g	5	25	high	high	ADJ
g158bg28j3g	5	26	-	-	PUNCT
g158bg28j3g	5	27	cost	cost	NOUN
g158bg28j3g	5	28	treatment	treatment	NOUN
g158bg28j3g	5	29	regimens	regimen	NOUN
g158bg28j3g	5	30	.	.	PUNCT
g158bg28j3g	6	1	other	other	ADJ
g158bg28j3g	6	2	chemotherapeutics	chemotherapeutic	NOUN
g158bg28j3g	6	3	like	like	ADP
g158bg28j3g	6	4	amphotericin	amphotericin	PROPN
g158bg28j3g	6	5	b	b	PROPN
g158bg28j3g	6	6	and	and	CCONJ
g158bg28j3g	6	7	miltefosine	miltefosine	NOUN
g158bg28j3g	6	8	are	be	AUX
g158bg28j3g	6	9	being	be	AUX
g158bg28j3g	6	10	more	more	ADV
g158bg28j3g	6	11	widely	widely	ADV
g158bg28j3g	6	12	used	use	VERB
g158bg28j3g	6	13	,	,	PUNCT
g158bg28j3g	6	14	but	but	CCONJ
g158bg28j3g	6	15	still	still	ADV
g158bg28j3g	6	16	face	face	VERB
g158bg28j3g	6	17	many	many	ADJ
g158bg28j3g	6	18	of	of	ADP
g158bg28j3g	6	19	the	the	DET
g158bg28j3g	6	20	same	same	ADJ
g158bg28j3g	6	21	limitations	limitation	NOUN
g158bg28j3g	6	22	as	as	ADP
g158bg28j3g	6	23	pentavalent	pentavalent	ADJ
g158bg28j3g	6	24	antimonials	antimonial	NOUN
g158bg28j3g	6	25	as	as	ADV
g158bg28j3g	6	26	well	well	ADV
g158bg28j3g	6	27	as	as	ADP
g158bg28j3g	6	28	the	the	DET
g158bg28j3g	6	29	emergence	emergence	NOUN
g158bg28j3g	6	30	of	of	ADP
g158bg28j3g	6	31	drug	drug	NOUN
g158bg28j3g	6	32	resistance	resistance	NOUN
g158bg28j3g	6	33	.	.	PUNCT
g158bg28j3g	7	1	there	there	PRON
g158bg28j3g	7	2	is	be	VERB
g158bg28j3g	7	3	an	an	DET
g158bg28j3g	7	4	important	important	ADJ
g158bg28j3g	7	5	need	need	NOUN
g158bg28j3g	7	6	for	for	ADP
g158bg28j3g	7	7	identifying	identify	VERB
g158bg28j3g	7	8	and	and	CCONJ
g158bg28j3g	7	9	developing	develop	VERB
g158bg28j3g	7	10	novel	novel	NOUN
g158bg28j3g	7	11	chemotherapeutics	chemotherapeutic	NOUN
g158bg28j3g	7	12	.	.	PUNCT
g158bg28j3g	8	1	we	we	PRON
g158bg28j3g	8	2	developed	develop	VERB
g158bg28j3g	8	3	a	a	DET
g158bg28j3g	8	4	novel	novel	NOUN
g158bg28j3g	8	5	,	,	PUNCT
g158bg28j3g	8	6	target	target	NOUN
g158bg28j3g	8	7	-	-	PUNCT
g158bg28j3g	8	8	free	free	ADJ
g158bg28j3g	8	9	fluorometric	fluorometric	ADJ
g158bg28j3g	8	10	high	high	ADJ
g158bg28j3g	8	11	-	-	PUNCT
g158bg28j3g	8	12	throughput	throughput	NOUN
g158bg28j3g	8	13	screen	screen	NOUN
g158bg28j3g	8	14	to	to	PART
g158bg28j3g	8	15	identify	identify	VERB
g158bg28j3g	8	16	small	small	ADJ
g158bg28j3g	8	17	molecules	molecule	NOUN
g158bg28j3g	8	18	with	with	ADP
g158bg28j3g	8	19	anti	anti	ADJ
g158bg28j3g	8	20	-	-	ADJ
g158bg28j3g	8	21	leishmanial	leishmanial	ADJ
g158bg28j3g	8	22	activity	activity	NOUN
g158bg28j3g	8	23	.	.	PUNCT
g158bg28j3g	9	1	of	of	ADP
g158bg28j3g	9	2	the	the	DET
g158bg28j3g	9	3	10,000	10,000	NUM
g158bg28j3g	9	4	compounds	compound	NOUN
g158bg28j3g	9	5	initially	initially	ADV
g158bg28j3g	9	6	screened	screen	VERB
g158bg28j3g	9	7	,	,	PUNCT
g158bg28j3g	9	8	109	109	NUM
g158bg28j3g	9	9	molecular	molecular	ADJ
g158bg28j3g	9	10	scaffolds	scaffold	NOUN
g158bg28j3g	9	11	were	be	AUX
g158bg28j3g	9	12	represented	represent	VERB
g158bg28j3g	9	13	within	within	ADP
g158bg28j3g	9	14	the	the	DET
g158bg28j3g	9	15	hit	hit	ADJ
g158bg28j3g	9	16	compounds	compound	NOUN
g158bg28j3g	9	17	;	;	PUNCT
g158bg28j3g	9	18	three	three	NUM
g158bg28j3g	9	19	of	of	ADP
g158bg28j3g	9	20	these	these	DET
g158bg28j3g	9	21	scaffolds	scaffold	NOUN
g158bg28j3g	9	22	warranted	warrant	VERB
g158bg28j3g	9	23	further	further	ADJ
g158bg28j3g	9	24	study	study	NOUN
g158bg28j3g	9	25	:	:	PUNCT
g158bg28j3g	9	26	2,4	2,4	NOUN
g158bg28j3g	9	27	-	-	PUNCT
g158bg28j3g	9	28	diaminoquinazoline	diaminoquinazoline	NOUN
g158bg28j3g	9	29	(	(	PUNCT
g158bg28j3g	9	30	2,4	2,4	NOUN
g158bg28j3g	9	31	-	-	PUNCT
g158bg28j3g	9	32	daq	daq	NUM
g158bg28j3g	9	33	)	)	PUNCT
g158bg28j3g	9	34	,	,	PUNCT
g158bg28j3g	9	35	1,4	1,4	AUX
g158bg28j3g	9	36	-	-	PUNCT
g158bg28j3g	9	37	diaryl	diaryl	PROPN
g158bg28j3g	9	38	-	-	PUNCT
g158bg28j3g	9	39	pyrazolo	pyrazolo	ADJ
g158bg28j3g	9	40	-	-	PUNCT
g158bg28j3g	9	41	pyridinone	pyridinone	PROPN
g158bg28j3g	9	42	(	(	PUNCT
g158bg28j3g	9	43	1,4	1,4	NOUN
g158bg28j3g	9	44	-	-	PUNCT
g158bg28j3g	9	45	dapp	dapp	ADJ
g158bg28j3g	9	46	)	)	PUNCT
g158bg28j3g	9	47	,	,	PUNCT
g158bg28j3g	9	48	and	and	CCONJ
g158bg28j3g	9	49	pyrazolo[5,1	pyrazolo[5,1	ADJ
g158bg28j3g	9	50	-	-	ADJ
g158bg28j3g	9	51	c][1,2,4]triazine	c][1,2,4]triazine	NOUN
g158bg28j3g	9	52	(	(	PUNCT
g158bg28j3g	9	53	ptz	ptz	PROPN
g158bg28j3g	9	54	)	)	PUNCT
g158bg28j3g	9	55	.	.	PUNCT
g158bg28j3g	10	1	utilizing	utilize	VERB
g158bg28j3g	10	2	mcherry	mcherry	PROPN
g158bg28j3g	10	3	fluorescent	fluorescent	PROPN
g158bg28j3g	10	4	leishmania	leishmania	PROPN
g158bg28j3g	10	5	donovani	donovani	PROPN
g158bg28j3g	10	6	and	and	CCONJ
g158bg28j3g	10	7	leishmania	leishmania	PROPN
g158bg28j3g	10	8	major	major	PROPN
g158bg28j3g	10	9	in	in	ADP
g158bg28j3g	10	10	in	in	ADP
g158bg28j3g	10	11	vitro	vitro	X
g158bg28j3g	10	12	and	and	CCONJ
g158bg28j3g	10	13	in	in	ADP
g158bg28j3g	10	14	vivo	vivo	ADJ
g158bg28j3g	10	15	efficacy	efficacy	NOUN
g158bg28j3g	10	16	studies	study	NOUN
g158bg28j3g	10	17	allowed	allow	VERB
g158bg28j3g	10	18	for	for	ADP
g158bg28j3g	10	19	easy	easy	ADJ
g158bg28j3g	10	20	,	,	PUNCT
g158bg28j3g	10	21	automated	automate	VERB
g158bg28j3g	10	22	quantification	quantification	NOUN
g158bg28j3g	10	23	of	of	ADP
g158bg28j3g	10	24	parasite	parasite	NOUN
g158bg28j3g	10	25	survival	survival	NOUN
g158bg28j3g	10	26	as	as	ADV
g158bg28j3g	10	27	well	well	ADV
g158bg28j3g	10	28	as	as	ADP
g158bg28j3g	10	29	real	real	ADJ
g158bg28j3g	10	30	-	-	PUNCT
g158bg28j3g	10	31	time	time	NOUN
g158bg28j3g	10	32	infection	infection	NOUN
g158bg28j3g	10	33	monitoring	monitoring	NOUN
g158bg28j3g	10	34	.	.	PUNCT
g158bg28j3g	11	1	the	the	DET
g158bg28j3g	11	2	1,4	1,4	PROPN
g158bg28j3g	11	3	-	-	PUNCT
g158bg28j3g	11	4	dapp	dapp	ADJ
g158bg28j3g	11	5	and	and	CCONJ
g158bg28j3g	11	6	ptz	ptz	NOUN
g158bg28j3g	11	7	scaffolds	scaffold	NOUN
g158bg28j3g	11	8	have	have	AUX
g158bg28j3g	11	9	not	not	PART
g158bg28j3g	11	10	been	be	AUX
g158bg28j3g	11	11	previously	previously	ADV
g158bg28j3g	11	12	identified	identify	VERB
g158bg28j3g	11	13	as	as	ADP
g158bg28j3g	11	14	anti	anti	NOUN
g158bg28j3g	11	15	-	-	NOUN
g158bg28j3g	11	16	leishmanials	leishmanial	NOUN
g158bg28j3g	11	17	;	;	PUNCT
g158bg28j3g	11	18	even	even	ADV
g158bg28j3g	11	19	more	more	ADV
g158bg28j3g	11	20	promising	promising	ADJ
g158bg28j3g	11	21	is	be	AUX
g158bg28j3g	11	22	that	that	SCONJ
g158bg28j3g	11	23	only	only	ADV
g158bg28j3g	11	24	5	5	NUM
g158bg28j3g	11	25	of	of	ADP
g158bg28j3g	11	26	the	the	DET
g158bg28j3g	11	27	55	55	NUM
g158bg28j3g	11	28	analogs	analog	NOUN
g158bg28j3g	11	29	we	we	PRON
g158bg28j3g	11	30	synthesized	synthesize	VERB
g158bg28j3g	11	31	exhibited	exhibit	VERB
g158bg28j3g	11	32	any	any	DET
g158bg28j3g	11	33	cytotoxic	cytotoxic	ADJ
g158bg28j3g	11	34	effects	effect	NOUN
g158bg28j3g	11	35	.	.	PUNCT
g158bg28j3g	12	1	in	in	ADP
g158bg28j3g	12	2	addition	addition	NOUN
g158bg28j3g	12	3	,	,	PUNCT
g158bg28j3g	12	4	we	we	PRON
g158bg28j3g	12	5	optimized	optimize	VERB
g158bg28j3g	12	6	both	both	PRON
g158bg28j3g	12	7	murine	murine	NOUN
g158bg28j3g	12	8	ear	ear	NOUN
g158bg28j3g	12	9	and	and	CCONJ
g158bg28j3g	12	10	footpad	footpad	NOUN
g158bg28j3g	12	11	infection	infection	NOUN
g158bg28j3g	12	12	models	model	NOUN
g158bg28j3g	12	13	of	of	ADP
g158bg28j3g	12	14	cutaneous	cutaneous	ADJ
g158bg28j3g	12	15	leishmaniasis	leishmaniasis	NOUN
g158bg28j3g	12	16	;	;	PUNCT
g158bg28j3g	12	17	using	use	VERB
g158bg28j3g	12	18	fluorescence	fluorescence	NOUN
g158bg28j3g	12	19	allowed	allow	VERB
g158bg28j3g	12	20	us	we	PRON
g158bg28j3g	12	21	to	to	PART
g158bg28j3g	12	22	monitor	monitor	VERB
g158bg28j3g	12	23	an	an	DET
g158bg28j3g	12	24	infection	infection	NOUN
g158bg28j3g	12	25	of	of	ADP
g158bg28j3g	12	26	a	a	DET
g158bg28j3g	12	27	single	single	ADJ
g158bg28j3g	12	28	mouse	mouse	NOUN
g158bg28j3g	12	29	over	over	ADP
g158bg28j3g	12	30	time	time	NOUN
g158bg28j3g	12	31	.	.	PUNCT
g158bg28j3g	13	1	we	we	PRON
g158bg28j3g	13	2	were	be	AUX
g158bg28j3g	13	3	able	able	ADJ
g158bg28j3g	13	4	to	to	PART
g158bg28j3g	13	5	identify	identify	VERB
g158bg28j3g	13	6	two	two	NUM
g158bg28j3g	13	7	potent	potent	ADJ
g158bg28j3g	13	8	1,4	1,4	ADJ
g158bg28j3g	13	9	-	-	PUNCT
g158bg28j3g	13	10	dapp	dapp	ADJ
g158bg28j3g	13	11	analogs	analog	NOUN
g158bg28j3g	13	12	that	that	PRON
g158bg28j3g	13	13	routinely	routinely	ADV
g158bg28j3g	13	14	exhibited	exhibit	VERB
g158bg28j3g	13	15	efficacy	efficacy	NOUN
g158bg28j3g	13	16	in	in	ADP
g158bg28j3g	13	17	our	our	PRON
g158bg28j3g	13	18	in	in	X
g158bg28j3g	13	19	vitro	vitro	X
g158bg28j3g	13	20	and	and	CCONJ
g158bg28j3g	13	21	in	in	ADP
g158bg28j3g	13	22	vivo	vivo	ADJ
g158bg28j3g	13	23	models	model	NOUN
g158bg28j3g	13	24	.	.	PUNCT